» Articles » PMID: 27589872

Maternal Extracellular Vesicles and Platelets Promote Preeclampsia Via Inflammasome Activation in Trophoblasts

Abstract

Preeclampsia (PE) is a placenta-induced inflammatory disease associated with maternal and fetal morbidity and mortality. The mechanisms underlying PE remain enigmatic and delivery of the placenta is the only known remedy. PE is associated with coagulation and platelet activation and increased extracellular vesicle (EV) formation. However, thrombotic occlusion of the placental vascular bed is rarely observed and the mechanistic relevance of EV and platelet activation remains unknown. Here we show that EVs induce a thromboinflammatory response specifically in the placenta. Following EV injection, activated platelets accumulate particularly within the placental vascular bed. EVs cause adenosine triphosphate (ATP) release from platelets and inflammasome activation within trophoblast cells through purinergic signaling. Inflammasome activation in trophoblast cells triggers a PE-like phenotype, characterized by pregnancy failure, elevated blood pressure, increased plasma soluble fms-like tyrosine kinase 1, and renal dysfunction. Intriguingly, genetic inhibition of inflammasome activation specifically in the placenta, pharmacological inhibition of inflammasome or purinergic signaling, or genetic inhibition of maternal platelet activation abolishes the PE-like phenotype. Inflammasome activation in trophoblast cells of women with preeclampsia corroborates the translational relevance of these findings. These results strongly suggest that EVs cause placental sterile inflammation and PE through activation of maternal platelets and purinergic inflammasome activation in trophoblast cells, uncovering a novel thromboinflammatory mechanism at the maternal-embryonic interface.

Citing Articles

Updates on neonatal cell and novel therapeutics: Proceedings of the Second Neonatal Cell Therapies Symposium (2024).

Paton M, Benders M, Blatch-Williams R, Dallimore E, Edwards A, Elwood N Pediatr Res. 2025; .

PMID: 39815092 DOI: 10.1038/s41390-025-03856-x.


Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology.

Mattuizzi A, Sauvestre F, Fargeix T, White E, Leibler C, Cargou M Nat Commun. 2024; 15(1):9396.

PMID: 39477918 PMC: 11525837. DOI: 10.1038/s41467-024-53591-w.


Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems.

Salavati M, Arabshomali A, Nouranian S, Shariat-Madar Z Molecules. 2024; 29(20).

PMID: 39459251 PMC: 11510185. DOI: 10.3390/molecules29204883.


DOCK1 deficiency drives placental trophoblast cell dysfunction by influencing inflammation and oxidative stress, hallmarks of preeclampsia.

Xu Y, Qin X, Zeng W, Wu F, Wei X, Li Q Hypertens Res. 2024; 47(12):3434-3446.

PMID: 39379467 DOI: 10.1038/s41440-024-01920-3.


Exploring the potential of in vitro extracellular vesicle generation in reproductive biology.

Franko R, de Almeida Monteiro Melo Ferraz M J Extracell Biol. 2024; 3(9):e70007.

PMID: 39238549 PMC: 11375532. DOI: 10.1002/jex2.70007.